Shifting Treatment Perspectives in Polycythemia Vera Real-World Experience with Ropeginterferon Alfa-2b

Prepared by Michelle Taymuree, PharmD, MBA, and NCODA for PharmaEssentia | August 2026

Is Polycythemia Vera Treatment Practice Keeping Pace with the Evidence?

The treatment landscape for polycythemia vera (PV) is evolving, with growing emphasis on long-term disease control, earlier use of interferon-based therapy, and individualized treatment strategies. But translating these advances into everyday practice can bring real operational and patient-care challenges.

This white paper, Shifting Treatment Perspectives in Polycythemia Vera: Real-World Experience with Ropeginterferon Alfa-2b, brings together perspectives from multidisciplinary oncology professionals to examine how ropeginterferon alfa-2b is being used in real-world practice and what may be influencing broader adoption.

Read the white paper to explore:

• How clinicians are thinking about the evolving role of ropeginterferon alfa-2b in PV
• Why access, workflow, and patient experience can influence treatment selection
• Practical strategies practices are using to support initiation and long-term management
• How medically integrated pharmacy and multidisciplinary care can help address implementation barriers
• What the newly approved BESREMi Pen™ may mean for administration and the patient experience
• Emerging evidence and the continued evolution of interferon-based therapy

See how multidisciplinary oncology teams are navigating the shift from treatment intent to real-world implementation in PV.

READ WHITEPAPER

References

1. Tefferi, Ayalew, Alessandro M. Vannucchi, and Tiziano Barbui. “Polycythemia Vera Treatment Algorithm 2018.” Blood Cancer Journal, vol. 8, no. 1, 2018, p. 3. Springer Nature, doi:10.1038/s41408-017-0042-7.
2. Gisslinger, Heinz, et al. “Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera (PROUD PV and CONTINUATION-PV): A Randomised, Non-Inferiority, Phase 3 Trial and Its Extension Study.” The Lancet Haematology, vol. 7, no. 3, 2020, pp. e196–e208. Elsevier, doi:10.1016/S2352-3026(19)30236-4.
3. Gisslinger, Heinz. Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. American Society of Hematology (ASH) Annual Meeting, 2020, www.mpn-advocates.net/wp-content/uploads/2021/11/Heinz-Gisslinger-ASH2020-60-months-data_Template_13Nov2020.pdf. Accessed 5 May 2026.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. NCCN, www.nccn.org. Accessed 26 Apr. 2026.
5. PharmaEssentia USA. “PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (Ropeginterferon Alfa-2b-njft) for Polycythemia Vera.” PharmaEssentia USA, 26 June 2026, https://us.pharmaessentia.com/pharmaessentia-announces-fda-approval-and-u-s-launch-of-besremi-pen-ropeginterferon-alfa-2b-njft-for-polycythemia-vera/. Accessed 6 July 2026.
6. ClinicalTrials.gov. “Low-PV: Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.” U.S. National Library of Medicine, clinicaltrials.gov/study/NCT05481151. Accessed 26 Apr. 2026.
7. Mesa, Ruben A., et al. “Ropeginterferon Alfa-2b in Hydroxyurea-Intolerant or Hydroxyurea-Refractory Essential Thrombocythaemia (SURPASS-ET): A Multicentre, Open-Label, Randomised, Active-Controlled, Phase 3 Study.” The Lancet Haematology, vol. 12, no. 11, 2025, pp. e862–e875. doi:10.1016/S2352-3026(25)00264-9.
8. Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Qin A, et al. Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American,
   single-arm, multicentre study (EXCEED-ET). Lancet Regional Health – Americas. 2026;61:101529.
9. National Community Oncology Dispensing Association (NCODA). “Oncology Optimized Limited Distribution (OOLD).” NCODA, ncoda.org/oold/. Accessed 5 May 2026.